Cipla Limited
CIPLA
Rang in aandelen
#1804
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aandeelprijs
$14.64
Marktkapitalisatie
$11.83B
Verandering (1 dag)
0.10%
Verandering (1 jaar)
-18.29%
Land
IN
Handel Cipla Limited (CIPLA)
Categorie
Healthcare
EPS voor Cipla Limited (CIPLA)
EPS per June 2026 TTM: $0.46
Volgens de laatste financiële rapporten en de aandelenkoers van Cipla Limited is de huidige EPS van het bedrijf (TTM) $0.46. Eind 2024 had het bedrijf een EPS van $0.61, een stijging ten opzichte van de EPS van 2023 die $0.42 bedroeg.
EPS-geschiedenis van Cipla Limited van 2004 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.46 | -39.39% |
| 2025 | $0.76 | 24.70% |
| 2024 | $0.61 | 44.90% |
| 2023 | $0.42 | 2.80% |
| 2022 | $0.41 | 0.88% |
| 2021 | $0.41 | 59.95% |
| 2020 | $0.25 | -6.77% |
| 2019 | $0.27 | 1.49% |
| 2018 | $0.27 | 39.41% |
| 2017 | $0.19 | -24.42% |
| 2016 | $0.26 | 8.40% |
| 2015 | $0.24 | -18.30% |
| 2014 | $0.29 | -18.53% |
| 2013 | $0.35 | 26.01% |
| 2012 | $0.28 | 1.66% |
| 2011 | $0.28 | -9.38% |
| 2010 | $0.31 | 56.09% |
| 2009 | $0.20 | -13.31% |
| 2008 | $0.23 | 13.49% |
| 2007 | $0.20 | 9.18% |
| 2006 | $0.18 | 45.52% |
| 2005 | $0.13 | 37.67% |
| 2004 | $0.09 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 20.78% |
IN
|
